2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      895E00BE431C5D109F968BA8D0506240 10.1002/acr.25240 Submitted for publication December 1, 2022; accepted in revised form July 3, 2023.  INTRODUCTION Glucocorticoids (GCs) remain a common therapeutic modality for patients with a variety of diseases. Prevention of GC-induced bone loss and fractures has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline development process and ACR policy guiding management of conflicts of interest